{"filing":{"accession_number":"0001104659-26-103316","cik":"0001512762","ticker":"CHRS","company_name":"Coherus Oncology, Inc.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"chrs-20260828x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/chrs-20260828x8k.htm"},"events":[{"id":30410,"run_id":27870,"accession_number":"0001104659-26-103316","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Coherus Oncology entered into an at-the-market (ATM) sales agreement with Leerink Partners to offer and sell up to $50 million of common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, disclosed via Item 8.01. The filing explicitly describes an \"at the market offering\" mechanism and establishes the framework for unregistered or registered equity sales that would dilute existing shareholders, making this material to investors assessing capital structure and ownership stakes.","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32989,"accession_number":"0001104659-26-103316","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Coherus Oncology entered into an at-the-market (ATM) sales agreement with Leerink Partners to offer and sell up to $50 million of common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, disclosed via Item 8.01. The filing explicitly describes an \"at the market offering\" mechanism and establishes the framework for unregistered or registered equity sales that would dilute existing shareholders, making this material to investors assessing capital structure and ownership stakes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T21:12:54.804126+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32989,"accession_number":"0001104659-26-103316","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Coherus Oncology entered into an at-the-market (ATM) sales agreement with Leerink Partners to offer and sell up to $50 million of common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, disclosed via Item 8.01. The filing explicitly describes an \"at the market offering\" mechanism and establishes the framework for unregistered or registered equity sales that would dilute existing shareholders, making this material to investors assessing capital structure and ownership stakes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T21:12:54.804126+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-28"}]}